title: MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines.
abstract: The World Health Organization (WHO) convened a malaria vaccines committee (MALVAC) scientific forum from 20 to 21 February 2012 in Geneva, Switzerland, to review the global malaria vaccine portfolio, to gain consensus on approaches to accelerate second-generation malaria vaccine development, and to discuss the need to update the vision and strategic goal of the Malaria Vaccine Technology Roadmap. This article summarizes the forum, which included reviews of leading Plasmodium falciparum vaccine candidates for pre-erythrocytic vaccines, blood-stage vaccines, and transmission-blocking vaccines. Other major topics included vaccine candidates against Plasmodium vivax, clinical trial site capacity development in Africa, trial design considerations for a second-generation malaria vaccine, adjuvant selection, and regulatory oversight functions including vaccine licensure.
authors.affiliation: Johns Hopkins Bloomberg School of Public Health, Johns HopkinsUniversity, Baltimore, Maryland, USA.
authors.forename: Kirsten S
authors.initials: KS
authors.lastname: Vannice
authors.forename: Graham V
authors.initials: GV
authors.lastname: Brown
authors.forename: Bartholomew D
authors.initials: BD
authors.lastname: Akanmori
authors.forename: Vasee S
authors.initials: VS
authors.lastname: Moorthy
mesh_terms: D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000517:prevention & control; D016780:Malaria, Vivax / Q000517:prevention & control; D010963:Plasmodium falciparum / Q000276:immunology*; D010966:Plasmodium vivax / Q000276:immunology*
chemical_list: D017780:Malaria Vaccines